Cargando…

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

BACKGROUND: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. OBJECTIVE: The objective of this commentary is to propose a useful cost-effective dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Zhifeng, Álvarez-Gonzalez, César, De Trane, Stefania, Yildiz, Ozlem, Albor, Christo, Doctor, Gabriel, Soon, Derek, Pepper, George, Turner, Benjamin P, Marta, Monica, Mathews, Joela, Giovannoni, Gavin, Baker, David, Schmierer, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077935/ https://www.ncbi.nlm.nih.gov/pubmed/30090639 http://dx.doi.org/10.1177/2055217318783767

Ejemplares similares

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
por: Allen-Philbey, Kimberley, et al.
Publicado: (2023)

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
por: Afolabi, Dayo, et al.
Publicado: (2017)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
por: Mateo-Casas, M., et al.
Publicado: (2020)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

Both cladribine and alemtuzumab may effect MS via B-cell depletion
por: Baker, David, et al.
Publicado: (2017)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
por: Stuve, Olaf, et al.
Publicado: (2019)

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
por: Rieckmann, Peter, et al.
Publicado: (2021)

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
por: Baker, David, et al.
Publicado: (2017)

The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
por: Baker, David, et al.
Publicado: (2020)

Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?
por: Allen-Philbey, Kimberley, et al.
Publicado: (2020)

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment
por: Kalatskaya, Irina, et al.
Publicado: (2023)

Cladribine/hydroxychloroquine: COVID-19-pneumonia, lymphopenia and off label use: case report
Publicado: (2020)

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
por: Comi, Giancarlo, et al.
Publicado: (2018)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2021)

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
por: De Stefano, Nicola, et al.
Publicado: (2021)

Application of population pharmacokinetics to cladribine
por: Lindemalm, Synnöve, et al.
Publicado: (2005)

Cladribine: Lymphopenia: case report
Publicado: (2021)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
por: Giovannoni, Gavin, et al.
Publicado: (2018)

Cladribine modifies functional properties of microglia
por: Jørgensen, L. Ø., et al.
Publicado: (2020)

Cladribine: Lymphopenia: 2 case reports
Publicado: (2020)

Immunomodulatory Effects Associated with Cladribine Treatment
por: Fissolo, Nicolás, et al.
Publicado: (2021)

The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
por: Baker, David, et al.
Publicado: (2023)

MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
por: Seferoğlu, Meral, et al.
Publicado: (2021)

MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses – Commentary
por: Schmierer, K, et al.
Publicado: (2021)

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
por: Schmierer, Klaus, et al.
Publicado: (2022)

Erdheim Chester Disease treated successfully with cladribine
por: Azadeh, Natalya, et al.
Publicado: (2016)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2018)

Expert-Agreed Practical Recommendations on the Use of Cladribine
por: Meca-Lallana, Virginia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aqdropsspo9mdkksk01ls3mcmb